You are here

Article Text

Article menu
Download PDFPDF
Prognosis
Cohort study
Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure
  1. Adrian F Hernandez1,
  2. Adam D DeVore2
  1. 1Department of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA;
  2. 2Duke University Medical Center, Durham, North Carolina, USA
  1. Correspondence to: Dr Adrian F Hernandez, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA; adrian.hernandez{at}duke.edu

https://doi.org/10.1136/eb-2014-101743

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ahmed A, Bourge RC, Fonarow GC, et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalised for heart failure. Am J Med 2014;127:61–70.OpenUrlCrossRefPubMed

    Context

    The use of digoxin for the treatment of heart failure dates back to the 18th century, yet controversy remains about its safety and efficacy. The largest clinical trial of digoxin concluded that digoxin had no effect on mortality but did improve the rate of rehospitalisation for patients with chronic heart failure.1 With increasing focus on readmissions, there are limited data to understand the impact of digoxin initiated during hospitalisation for acute heart failure on postdischarge outcomes.

    Methods

    The authors analysed data from chart abstractions and Medicare claims of patients hospitalised with acute heart failure to assess the impact of digoxin on postdischarge …

    View Full Text

    Footnotes

    • Competing interests None.